GSK has acquired the privately held biotechnology company Domantis Ltd. for £230 million ($454 million) in cash.
Domantis, based in Cambridge, England, is a specialist in next-generation monoclonal antibodies, which are derived from a single clone of a cell and used to target various diseases. It is currently developing drugs to treat diseases such as rheumatoid arthritis, asthma, chronic obstructive pulmonary disease and multiple myeloma, a type of bone marrow cancer.
The acquisition follows a similar deal by rival AstraZeneca, which took over antibody specialist Cambridge Antibody Technologies in May.
No comments:
Post a Comment